Introduction
death, cancers, cancer, cancer death, deaths
CANCERS, CANCER, DISEASE, CERVICAL CANCER, CERVICAL CANCER
Cervical cancer is the fourth most prevalent cancer and the fourth leading cause of cancer death in women, with approximately 604,000 new cases and 342,000 cervical cancer-related deaths worldwide in 2020 (Targeting the programmed death-1 (PD-1)/programmed death ligand 1 (PD-L1) axis is a promising treatment strategy for cervical cancer. This is supported by the observation that human papillomavirus, the main causative agent for cervical cancer, increased PD-L1 expression and thereby induced immune evasion in this disease (Before immune checkpoint inhibitors were investigated in multiple clinical trials, systemic agents such as taxanes and platinum-based chemotherapy were commonly used. Nanoparticle albumin-bound (nab)-paclitaxel is one such chemotherapeutic option, recording the highest ORR (28.6%) when given as a single agent against drug-resistant cervical cancer compared with other chemotherapies (Serplulimab (formerly HLX10) is a novel humanized immunoglobulin G4 anti–PD-1 monoclonal antibody that has shown antitumor activity and a manageable safety profile in a variety of cancers (We conducted a phase II trial to assess the efficacy and safety of serplulimab in combination with nab-paclitaxel in patients with advanced cervical cancer who had progressed on or were unable to tolerate first-line standard chemotherapy.